COMPANY OVERVIEW
BERG Analytics takes artificial intelligence to a level never before seen in the world of analytics by providing real-time predictive and prescriptive solutions to optimize patient treatments and improve population health.
Our innovative machine learning platform, bAIcisTM, uses powerful artificial intelligence technology to deliver new insights and, with our skilled and experienced team, promote best practices to dramatically reduce adverse events and readmissions, while supporting value-based care initiatives.
BERG Analytics provides healthcare stakeholders with Actionable Patient IntelligenceTM to support the drive for better outcomes for healthcare companies and the patients they serve.
OUR PARENT COMPANY, BERG
BERG, LLC is a diversified biopharmaceutical company with Analytics, Pharma, Biosystems and Diagnostics business divisions. BERG’s research seeks to understand how alterations in metabolism relate to disease onset. The BERG research team has uncovered key insight into metabolic control factors and into the underlying elements in the Warburg Hypothesis. The company has a deep pipeline of preclinical assets in CNS and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemo-toxicity. Armed with the use of the Interrogative Biology® discovery platform, BERG is poised to realize its pursuit of a healthier tomorrow.
Niven R. Narain, Ph.D.
Co-Founder, President & CEO of BERG
Niven’s foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics. As CEO, Niven drives the vision of BERG’s translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development.
He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.
Niven is former Director of Cutaneous Oncology at the Miller School of Medicine where he received graduate training in cancer biology and clinical dermatology research. He is the recipient of an NIH Award of Excellence. He currently serves on the NASA Gene Lab Steering committee and oversees key DoD and academic relationships for BERG.
Niven is an industry thought leader and has spoken at events for Aspen Ideas, Wired, Economist, and Bloomberg. He was honored by the Boston Business Journal top leaders 40 under 40 (2014). He is a St. John’s University Boston Chapter alumni advisor and is an active member of the Trinity Church Boston.
Slava Akmaev, Ph.D.
Co-Founder & Division Head
Slava Akmaev, Ph.D., is the Senior Vice President and Chief Analytics Officer at BERG, leading the Analytics division with over 18 years of industry experience. He is responsible for supporting BERG’s drug and diagnostic development programs with data science efforts using BERG’s proprietary artificial intelligence (AI) platform, bAIcis®. Dr. Akmaev is an advocate for the application of AI tools in digital healthcare and is a frequent speaker at AI industry events.
Dr. Akmaev is an inventor on 10+ pending and issued patents and an author on more than 20 peer-reviewed publications, book chapters, and 100+ presentations/ posters.
Prior to his role at BERG, Dr. Akmaev was the Scientific Associate Director at Genzyme Genetics where he launched multiple commercial diagnostic products. While at Genzyme R&D, he led the development of novel statistical approaches for high-throughput “omics” data and performed analytical work in genomics and genetics.
Dr. Akmaev published numerous manuscripts in genomics and was one of the early developers of analytical methodology around high-throughput molecular data. He co-authored the publication of the Long SAGE™ technology, “Using the transcriptome to annotate the genome” in Nature Biotechnology.
Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.
Vijetha Vemulapalli, Ph.D.
Director, Digital Health
Vijetha Vemulapalli, PH.D., is the Director of Digital Health at BERG Analytics and is the lead for Digital Health research and projects. During her time at BERG, she has utilized her extensive expertise in developing and applying analytical solutions to effectively lead her team towards finding innovative solutions to problems in Healthcare.
Dr. Vemulapalli has a background in Computer Science and Engineering and earned her Ph.D. in Computational Bioscience from the University of Colorado, Denver. She brings with her, strong computational skills and a unique perspective from her diverse work experience ranging from pharmaceutical R&D to various academic research labs. Her primary interest is in identifying, developing and optimizing meaningful computational solutions to clinically relevant problems.
Currently, at BERG, Dr. Vemulapalli’s focus is in the application of machine learning tools to disparate healthcare data for the development of predictive algorithms for population management and individualized patient care.
Leonardo Rodrigues, Ph.D.
Senior Director, AI and Machine Learning
Combining his Academic and Enterprise experience, Dr. Rodrigues holds more than 15 years of experience in data analysis and R&D. With a solid background in computer science, biology, and systems engineering, Dr. Rodrigues is a reference in applying AI and advanced analytical methods to extract actionable insights from clinical and biological data.
Dr. Rodrigues was the pioneer data-scientist at BERG, leading the design and development for ETL and data-analysis as well as the architectural lead responsible for implementing the current infrastructure used by BERG Analytics. Currently, Senior Director, AI and Machine Learning, Dr. Rodrigues leads the research and analysis of disruptive projects, as well as the development and deployment of innovative analytics technologies and IT platforms.
Dr. Rodrigues holds a B.Tech. in Data Processing, a B.S. in Molecular Sciences and a Ph.D. in Biochemistry. Prior to joining BERG, he concluded his postdoctoral studies at the Whitehead Institute-MIT, where he applied statistics, bioinformatics, and molecular/cell biology to study the role of cancer stem cells in tumor development and metastasis initiation.
CAREERS
Please visit BERG Health to view currently open positions.
News
The State of AI in Pharmaceutical Drug DevelopmentNovember 18, 2018 - 7:45 pm
Berg Analytics to Present at the AMIA 2018 Annual SymposiumNovember 2, 2018 - 7:43 pm
Fortune.com: 3 Ways AI Is Changing HealthcareOctober 22, 2018 - 7:50 pm
Big Data: Is It Crunch Time for Pharma?September 17, 2017 - 8:32 am
AI in Medicine Journal: Berg Analytics Research PaperSeptember 17, 2017 - 8:32 am